Suscribirse

Evaluation of beta-thalassemia in the fetus through cffDNA with multiple polymorphisms as a haplotype in the beta-globin gene - 06/11/20

Doi : 10.1016/j.tracli.2020.05.003 
Nadia Mirzaei Gisomi a, Gholamreza Javadi a, Shohre Zare Karizi b, Mohammad Miryounesi c, Parvaneh Keshavarz d, e,
a Department of biology, science and research branch, Islamic Azad university, Tehran, Iran 
b Department of biology, faculty of biological sciences, Islamic Azad university, Varamin-Pishva Branch, Varamin, Iran 
c Department of medical genetics, Shahid Beheshti university of medical sciences, Tehran, Iran 
d Cellular and molecular research center, faculty of medicine, Guilan university of medical sciences, Rasht, Iran 
e Medical genetics laboratory, Rasht, Iran 

Corresponding author. Cellular and molecular research center, faculty of medicine, Guilan university of medical sciences, Rasht, Iran.Cellular and molecular research center, faculty of medicine, Guilan university of medical sciencesRashtIran

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

páginas 10
Iconografías 6
Vídeos 0
Otros 0

Abstract

Objective

Invasive biopsy during the pregnancy is associated with an abortion risk of approximately 1% for the fetus. Free fetal DNA in maternal plasma is an excellent source of genetic material for prenatal molecular diagnoses. This study was conducted to investigate beta-thalassemia mutation in the fetus through maternal blood with multiple polymorphisms as haplotypes in the beta-globin gene.

Methods

In this study, a total of 33 beta-thalassemia carrier (minor) couples were genotyped by ARMS-PCR for IVSII-IG>A mutation. During pregnancy, 10mL of blood was collected from pregnant women, and DNA was extracted by the magnetic bead-based extraction, and fetal DNA was enriched with AMPure XP kit. Five polymorphisms in 4 haplotype groups were evaluated by the Sanger Sequencing method. Finally, results were compared with those of the invasion method.

Results

Participants in study were 33 couples, mean age of the men was 26±5 years, and mean age of women was 23±4 years, and mean MCV, MCH, HbA2 blood parameters were 62.4±5.3, 19.6±3.1, 4.2±2.1 respectively. A total of 33 fetuses were genotyped for IVSII-IG>A mutation. Nine fetuses were affected, 10 fetuses were normal and 14 fetuses were carrier of beta-thalassemia. Sensitivity and specificity of Sanger Sequencing were equal to 88.8% and 91.6% respectively. Positive and negative predictive values were obtained as 80% and 95.6%, respectively.

Conclusion

Mutational status of the fetus can be assessed by determining inheritance of paternally-derived alleles based on detection of haplotype-associated SNP in maternal plasma. Magnetic-based DNA extraction and fetal DNA enrichment are very simple and easy to perform and have satisfactory accuracy.

El texto completo de este artículo está disponible en PDF.

Keywords : Beta-thalassemia, Prenatal diagnosis (PND), Cell-free fetal DNA, Single nucleotide polymorphism (SNP), Haplotype, Beta-globin Gene


Esquema


© 2020  Publicado por Elsevier Masson SAS.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 27 - N° 4

P. 243-252 - novembre 2020 Regresar al número
Artículo precedente Artículo precedente
  • Viral metagenomics in Brazilian multiply transfused patients with sickle cell disease as an indicator for blood transfusion safety
  • I. Nunes Valença, A.C. Silva-Pinto, W. Araújo da Silva Júnior, D. Tadeu Covas, S. Kashima, S. Nanev Slavov
| Artículo siguiente Artículo siguiente
  • ABO blood group system is associated with COVID-19 mortality: An epidemiological investigation in the Indian population
  • Sunali Padhi, Subham Suvankar, Debabrata Dash, Venketesh K. Panda, Abhijit Pati, Jogeswar Panigrahi, Aditya K. Panda

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
La compra de artículos no está disponible en este momento.

¿Ya suscrito a @@106933@@ revista ?

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2024 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.